Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer
Top Cited Papers
Open Access
- 26 July 2007
- Vol. 110 (7) , 1493-1500
- https://doi.org/10.1002/cncr.22933
Abstract
BACKGROUND. The use of androgen deprivation therapy (ADT) in the treatment of men with prostate cancer has risen sharply. Although cardiovascular disease is the most common reason for death among men with prostate cancer who do not die of the disease itself, data regarding the effect of ADT on cardiovascular morbidity and mortality in men with prostate cancer are limited. In the current study, the authors attempted to measure the risk for subsequent cardiovascular morbidity in men with prostate cancer who received ADT. METHODS. A cohort of newly diagnosed men in a population-based registry who were diagnosed between 1992 and 1996 were identified retrospectively. A total of 22,816 subjects were identified after exclusion criteria were applied. Using a multivariate model, the authors calculated the risk of subsequent cardiovascular morbidity in men with prostate cancer who were treated with ADT, as defined using Medicare claims. RESULTS. Newly diagnosed prostate cancer patients who received ADT for at least 1 year were found to have a 20% higher risk of serious cardiovascular morbidity compared with similar men who did not receive ADT. Subjects began incurring this higher risk within 12 months of treatment. However, Hispanic men were found to have a lowered risk for cardiovascular morbidity. CONCLUSIONS. ADT is associated with significantly increased cardiovascular morbidity in men with prostate cancer and may lower overall survival in men with low-risk disease. These data have particular relevance to decisions regarding the use of ADT in men with prostate cancer in settings in which the benefit has not been clearly established. For men with metastatic disease, focused efforts to reduce cardiac risk factors through diet, exercise, or the use of lipid-lowering agents may mitigate some of the risks of ADT. Cancer 2007. © 2007 American Cancer Society.Keywords
This publication has 31 references indexed in Scilit:
- Diabetes and Cardiovascular Disease During Androgen Deprivation Therapy for Prostate CancerJournal of Clinical Oncology, 2006
- Population‐attributable risk of coronary heart disease risk factors during long‐term follow‐up: the Malmö Preventive ProjectJournal of Internal Medicine, 2006
- The third analysis of the bicalutamide Early Prostate Cancer programmeBJU International, 2006
- Changes in bone mineral density and body composition during initial and long‐term gonadotropin‐releasing hormone agonist treatment for prostate carcinomaCancer, 2005
- Long-Term Survival Rates of Patients With Prostate Cancer in the Prostate-Specific Antigen Screening Era: Population-Based Estimates for the Year 2000 by Period AnalysisJournal of Clinical Oncology, 2005
- The vasodilatory action of testosterone: a potassium‐channel opening or a calcium antagonistic action?British Journal of Pharmacology, 2003
- Transdermal Testosterone Gel Improves Sexual Function, Mood, Muscle Strength, and Body Composition Parameters in Hypogonadal MenJournal of Clinical Endocrinology & Metabolism, 2000
- Effect of Testosterone Treatment on Body Composition and Muscle Strength in Men Over 65 Years of AgeJournal of Clinical Endocrinology & Metabolism, 1999
- The relationship of natural androgens to coronary heart disease in males: a reviewAtherosclerosis, 1996
- Effect of testosterone on atherogenesis in cholesterol-fed rabbits with similar plasma cholesterol levelsAtherosclerosis, 1993